DIRECTORS
Arthur L. Rosenthal, CEO Cappella Inc.
Dr. Rosenthal is currently CEO of Cappella, Inc., a medical device company focused on coronary artery disease. He has previously served as Chairman and CEO of Labcoat Ltd. (Galway, Ireland), Senior Vice President and Chief Scientific Officer of Boston Scientific Corporation, VP of Research & Development for Johnson & Johnson Medical and VP Research & Development at CR Bard. He has been Chairman, Industrial Advisory Board, Department of Biomedical Engineering, Boston University and Adjunct Professor, Translational Biomedical Engineering, Boston University, Dept of Biomedical Engineering. Art has served as Director on Renovo, Ltd., UK (Non Executive Director, Chairman, Remuneration Committee), Labcoat Ltd., Ireland (Chairman, BOD) Cyberonics, Inc, Houston, Tx,,(Non Executive Director, Chairman, Compensation Committee Dr. Rosenthal received his Ph.D. in Biochemistry from the University of Massachusetts.
Jeff Courtney, General Partner, VenGrowth Private Equity
Mr. Courtney joined VenGrowth Private Equity Partners Inc. in 2002. He has 25 years of experience in the life sciences industry with expertise in quality assurance, regulatory, business development, marketing and sales. Jeff has a proven track record of building organizations and driving revenue growth for both emerging and established life sciences firms. Prior to joining VenGrowth, Jeff served as Partner and Co-President of the Scientific Advisory Board at CDP Capital, Technology Ventures, President of Hospital Pharmaceuticals at Faulding Canada Inc, EVP Marketing and Sales for Pharmascience Inc., and in numerous senior leadership roles with Johnson & Johnson Medical Products. He is an active board member of VisualSonics Inc., Axela Biosensors Inc., Zelos Therapeutics Inc., Metrigenix Inc., Kadmus Pharmaceuticals Inc., and Activbiotics Inc.
Denis Ho, Managing Director of Life Sciences, BDC Venture Capital
Mr. Ho joined BDC Venture Capital in 2003 as Managing Director, Life Sciences. Denis has over 20 years of experience in the North American financial markets including MDS Capital Corp as venture partner, Forbes Capital Canada Inc. as partner, KPMG as partner and Mercantile Bank of Canada as account manager. Denis holds an MBA from University of Western Ontario, M.Sc. in Medical Microbiology from Queen's University and a B.Sc., from the University of Toronto.
Lily Lam, Vice President, Investments, Covington Capital Partners
Lily joined Covington in November 2000. Her responsibilities include assessing new business opportunities, negotiating and structuring transactions and actively advising investee companies in a variety of sectors including healthcare, media, software and service. Prior to joining Covington, Lily held various management positions within several early-stage healthcare companies where she provided expertise in finance, operations and strategic direction. Lily holds an MBA from York University and an M.Sc. from the University of Toronto. She currently sits as a Director on the Boards of BTE Technologies Inc., Insception Biosciences Inc. and Bedlam Games.
Thomas P. Reeves, President & CEO
Mr. Reeves is President and CEO of Interface Biologics. A more detailed description of his credentials is included in the "Our Management" section of this website. (more>)
Paul Santerre, Ph.D., Chief Scientific Officer, Interface Biologics Inc.
Dr. Santerre is the founder and Chief Scientific Officer of Interface Biologics and a full professor of biomaterials at the University of Toronto. A more detailed biography is included in the “Our Management” section of this website. (more>)
